Calcitonin

Rheumatic Disease Clinics of North America

Volumn 27, Issue 1, 2001, Pages 187-196

  Silverman, Stuart L ^b  

^a OMC Clinical Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; CORTICOSTEROID; PARATHYROID HORMONE; SALCATONIN; VITAMIN D;

BONE DENSITY; BONE MASS; BONE TURNOVER; CLINICAL TRIAL; DRUG INDUCED DISEASE; HORMONE SUBSTITUTION; HUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

EID: 0035084308     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70193-9     Document Type: Article

References (46)

1. Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis
2. 25 Years of salmon calcitonin: From synthesis to therapeutic use
3. Intranasal salmon calcitonin (INSC) 50-200 IU does not prevent bone loss in early postmenopausal women
4. Calcium metabolism and 47 calcium kinetics before and after long-term thyrocalcitonin treatment in senile osteoporosis
5. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin
6. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fracture Study
7. Bone turnover in postmenopausal osteoporosis: Effect of calcitonin treatment
8. Intranasal calcitonin for the prevention and treatment of postmenopausal osteoporosis: A double blind placebo controlled study
9. Long-term tolerability of nasal spray formulation of salmon calcitonin
10. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss
11. Side effects of synthetic salmon and human calcitonin
12. Symptomatic treatment of osteoporosis-the pain model
13. Long-term calcitonin therapy in postmenopausal osteoporosis
14. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients
15. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture
16. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: Evidence of maximal effect after 8 weeks of continuous treatment
17. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow up study
18. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double blind placebo controlled clinical study
19. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures: A double blind placebo controlled study
20. Analgesic effect of salmon calcitonin suppositories in patients with bone pain
21. Effect of the intraperitoneal administration of salmon calcitonin on the actions of opioid agonists
22. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double blind clinical study
23. Effects of salmon calcitonin on the bone loss induced by ovariectomy
24. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women
25. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women
26. Calcitonin treatment of postmenopausal osteoporosis. Evaluation of efficacy by primary component analysis
27. Prevention of corticosteroid induced osteoporosis with salmon calcitonin in sarcoid patients
28. Suppression of bone resorption in early postmenopausal women by intranasal salmon calcitonin in relation to dosage and basal bone turnover
29. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose response study
30. Dose response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women
31. Effect of salcatonin given intranasally on early postmenopausal bone loss
32. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose response study
33. Nasal calcitonin for treatment of established osteoporosis
34. Analgesic effect of intranasal and intramuscular salmon calcitonin in postmenopausal osteoporosis: A double blind, double placebo study
35. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures
36. Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone
37. Longterm (3 years) prevention of trabecular postmenopausal bone loss with low dose intermittent nasal salmon calcitonin
38. 1 Year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin
39. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
40. Salmon calcitonin in the therapy of corticosteroid induced osteoporosis
41. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin
42. An evaluation of antibodies and clinical resistance to salmon calcitonin
43. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation
44. Effects of salmon calcitonin on skeletal mass in osteoporosis